Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL6000403 | 0.89 | SLC6A4 (0.47) | HTR2AHTR2CSLC6A4HTR1AKCNH2 | |
| Formic Acid SCHEMBL6000453 | 0.88 | HTR2A (0.37) | HTR2AHTR2CSLC6A4HTR1ANR3C1 | |
| SCHEMBL6000452 | 0.82 | HTR2A (0.41) | HTR2AHTR2CSLC6A4HTR1ANR3C1 | |
| Formic Acid SCHEMBL5999499 | 0.80 | SLC6A4 (0.45) | HTR2ASLC6A4KCNH2 | |
| Formic Acid SCHEMBL6000262 | 0.80 | SLC6A4 (0.45) | HTR2ASLC6A4KCNH2RAB9A | |
| Formic Acid SCHEMBL6000411 | 0.76 | PARP1 (0.38) | HTR2AHTR2CSLC6A4HTR1AKCNH2 | |
| Formic Acid SCHEMBL6000426 | 0.72 | SLC6A4 (0.48) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL6000410 | 0.70 | HTR2A (0.39) | HTR2AHTR2CSLC6A4HTR1AKCNH2 | |
| Formic Acid SCHEMBL5999788 | 0.69 | HTR2A (0.46) | HTR2ASLC6A4KCNH2 | |
| Formic Acid SCHEMBL6000270 | 0.68 | FFAR1 (0.39) | HTR2ASLC6A4KCNH2SLC6A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | HTR2A 7/4885HTR2C 2/4885SLC6A4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.